Browsing Tag
antibody drug conjugate
8 posts
Can AstraZeneca’s collaboration with Turbine speed up ADC drug discovery through AI simulation?
AstraZeneca joins hands with AI biotech Turbine to revolutionize antibody-drug conjugate discovery using virtual disease models and lab-in-the-loop design.
MediLink Therapeutics, BioNTech expand partnership with new $1.8bn agreement
MediLink Therapeutics (Suzhou) Co., Ltd., a prominent clinical-stage biotech company, has entered into a significant new strategic collaboration…
FDA grants full approval to AbbVie’s ovarian cancer drug ELAHERE
AbbVie (NYSE: ABBV) has achieved a significant milestone in the fight against ovarian cancer with the U.S. Food…
Enhertu shows promising results in DESTINY-PanTumor02 Phase 2 trial
The DESTINY-PanTumor02 Phase II trial revealed high-level results for AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), showcasing clinically…
LaNova Medicines, AstraZeneca sign $600m worth licensing deal for LM-305
LaNova Medicines has signed an exclusive license deal worth over $600 million for its pre-clinical stage antibody drug…
Enhertu EU approval : Daiichi Sankyo, AstraZeneca get approval for HER2 low metastatic breast cancer
Daiichi Sankyo and AstraZeneca have received the approval of the European Union (EU) for their jointly developed Enhertu…
AstraZeneca, Daiichi Sankyo get Enhertu FDA approval for HER2-low metastatic breast cancer
Enhertu FDA approval : AstraZeneca and Daiichi Sankyo have secured approval for Enhertu (trastuzumab deruxtecan) from the US…
DESTINY-Gastric02 phase 2 trial results : Enhertu shows clinically meaningful and durable tumor response
AstraZeneca said that Enhertu (trastuzumab deruxtecan) has shown clinically meaningful and durable response in the DESTINY-Gastric02 phase 2…